New drug takes aim at silent liver virus
NCT ID NCT03365947
Summary
This early-stage study tested a new drug called ARO-HBV for treating Hepatitis B. It first checked the drug's safety in healthy volunteers, then looked at its effects in people with the virus. The main goal was to see if the drug was safe and how the body processed it, while also measuring its initial impact on the Hepatitis B infection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Grafton, Auckland, 1010, New Zealand
-
Research Site 2
Papatoetoe, Auckland, 2025, New Zealand
-
Research Site 3
Melbourne, Victoria, 3065, Australia
-
Research Site 4
Clayton, Victoria, 3168, Australia
-
Research Site 5
Camperdown, New South Wales, 2050, Australia
-
Research Site 6
Nedlands, Western Australia, 6009, Australia
-
Research Site 7
Hong Kong, Hong Kong
Conditions
Explore the condition pages connected to this study.